Harry Shuman Biography and Net Worth

VP of Merus

Harry Shuman is the VP of Merus.

What is Harry Shuman's net worth?: The estimated net worth of Harry Shuman is at least $990.18 thousand as of November 26th, 2025. Shuman owns 11,002 shares of Merus stock worth more than $990,180 as of January 14th. This net worth approximation does not reflect any other investments that Shuman may own. Learn More about Harry Shuman's net worth.
How do I contact Harry Shuman?: The corporate mailing address for Shuman and other Merus executives is YALELAAN 62, UTRECHT P7, 3584 CM. Merus can also be reached via phone at (130) 253-8800 and via email at [email protected]. Learn More on Harry Shuman's contact information.
Has Harry Shuman been buying or selling shares of Merus?: Harry Shuman has not been actively trading shares of Merus over the course of the past ninety days. Most recently, Harry Shuman sold 1,700 shares of the business's stock in a transaction on Wednesday, November 26th. The shares were sold at an average price of $96.10, for a transaction totalling $163,370.00. Following the completion of the sale, the vice president now directly owns 11,002 shares of the company's stock, valued at $1,057,292.20. Learn More on Harry Shuman's trading history.
Who are Merus' active insiders?: Merus' insider roster includes Lex Bakker (SVP), Kruif de Kruif (SVP), Sven Lundberg (President, Chief Executive Officer, Executive Director), Harry Shuman (VP), and Peter Silverman (EVP, Chief Operating Officer, & General Counsel). Learn More on Merus' active insiders.
Are insiders buying or selling shares of Merus?: In the last year, Merus insiders bought shares 10 times. They purchased a total of 2,421,216 shares worth more than $234,857,952.00. In the last year, insiders at the biotechnology company sold shares 6 times. They sold a total of 92,500 shares worth more than $5,545,846.00. The most recent insider tranaction occured on December, 29th when Major Shareholder A/S Genmab bought 1,052,806 shares worth more than $102,122,182.00. Insiders at Merus own 3.7% of the company. Learn More about insider trades at Merus.
Information on this page was last updated on 12/29/2025.

Harry Shuman Insider Trading History at Merus

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/26/2025	Sell	1,700	$96.10	$163,370.00	11,002
11/25/2025	Sell	8,300	$95.92	$796,136.00	11,002
6/12/2024	Sell	7,300	$57.84	$422,232.00	7,002
6/10/2024	Sell	1,000	$53.22	$53,220.00	7,002
6/4/2024	Sell	6,000	$52.89	$317,340.00	7,002
12/19/2023	Sell	115	$26.68	$3,068.20	7,002
12/1/2023	Sell	575	$24.58	$14,133.50	7,367
6/1/2023	Sell	575	$21.48	$12,351.00	5,442
12/13/2022	Sell	168	$13.85	$2,326.80	3,517
12/1/2022	Sell	575	$15.35	$8,826.25	3,685
8/25/2022	Sell	165	$24.33	$4,014.45	1,760

Harry Shuman Buying and Selling Activity at Merus

Merus Company Overview

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Today's Range

Now: $90.00

$87.14

$96.86

50 Day Range

MA: $94.73

$90.00

$97.01

2 Week Range

Now: $90.00

$33.19

$97.14

Volume

2,728,600 shs

Average Volume

1,010,333 shs

Market Capitalization

$6.83 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.06